Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07239336 · ClinicalTrials.gov registry record · Phase 2
Study of DONQ52 in Active Celiac Disease
A Phase 2 study of Celiac Disease, sponsored by Chugai Pharmaceutical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 11
- Study locations
NCT07239336 is a Phase 2 study of Celiac Disease that is actively recruiting participants, run by Chugai Pharmaceutical. The registered enrollment target is 92 participants, below the 1,976-participant average among 24 other Celiac Disease trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT07239336, a Phase 2 study of Celiac Disease, is actively recruiting participants, sponsored by Chugai Pharmaceutical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
Conditions Studied
Interventions
- DRUG Placebo DONQ52
- DIETARY_SUPPLEMENT Simulated Inadvertent Gluten Exposure (SIGE) capsule
- DRUG DONQ52
Study Locations (11)
Florida
- Novum Clinical Research - Clermont
- Wellness Clinical Research - Miami Lakes
- Guardian Angel Research Center - Tampa
Arizona
- Chandler Clinical Trials - Chandler
- Scottsdale Clinical Trials - Scottsdale
Colorado
- Associates in Gastroenterology, PC - Colorado Springs
Connecticut
- Stamford Therapeutics Consortium - Stamford
Maine
- Portland Gastroenterology Center - Portland
Ohio
- Great Lakes Gastroenterology Research, LLC - Mentor
Pennsylvania
- Susquehanna Research Group, LLC - Harrisburg
Texas
- Vitality Clinical Research - Katy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2027-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07239336
The ClinicalTrials.gov registry entry for NCT07239336 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,976-participant average among 24 other Celiac Disease trials with a reported enrollment target (95% lower). The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo DONQ52 is the first listed.
NCT07239336 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT07239336 about?
NCT07239336 is a clinical study titled "Study of DONQ52 in Active Celiac Disease". The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
What is the current status of trial NCT07239336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2025-12-16. Estimated completion is 2027-12-15.
What conditions does trial NCT07239336 study?
This clinical trial studies the following conditions: Celiac Disease.
What interventions are being tested in trial NCT07239336?
The interventions under investigation include: Placebo DONQ52 (DRUG), Simulated Inadvertent Gluten Exposure (SIGE) capsule (DIETARY_SUPPLEMENT), DONQ52 (DRUG).
Who is sponsoring clinical trial NCT07239336?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07239336 being conducted?
This trial has 11 study locations across Arizona, Colorado, Connecticut, Florida, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
-
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
RECRUITING · Phase 2
-
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
COMPLETED · Phase 2
-
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
COMPLETED · Phase 2
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.